Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells. Issue 20 (7th September 2022)
- Record Type:
- Journal Article
- Title:
- Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells. Issue 20 (7th September 2022)
- Main Title:
- Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells
- Authors:
- Nishikubo, Kou
Ohgaki, Ryuichi
Okanishi, Hiroki
Okuda, Suguru
Xu, Minhui
Endou, Hitoshi
Kanai, Yoshikatsu - Abstract:
- Abstract: L‐type amino acid transporter 1 (LAT1; SLC7A5), which preferentially transports large neutral amino acids, is highly upregulated in various cancers. LAT1 supplies cancer cells with amino acids as substrates for enhanced biosynthetic and bioenergetic reactions and stimulates signalling networks involved in the regulation of survival, growth and proliferation. LAT1 inhibitors show anti‐cancer effects and a representative compound, JPH203, is under clinical evaluation. However, pharmacological impacts of LAT1 inhibition on the cellular amino acid transport and the translational activity in cancer cells that are conceptually pivotal for its anti‐proliferative effect have not been elucidated yet. Here, we demonstrated that JPH203 drastically inhibits the transport of all the large neutral amino acids in pancreatic ductal adenocarcinoma cells. The inhibitory effects of JPH203 were observed even in competition with high concentrations of amino acids in a cell culture medium. The analyses of the nutrient‐sensing mTORC1 and GAAC pathways and the protein synthesis activity revealed that JPH203 downregulates the global translation. This study demonstrates a predominant contribution of LAT1 to the transport of large neutral amino acids in cancer cells and the suppression of protein synthesis by JPH203 supposed to underly its broad anti‐proliferative effects across various types of cancer cells.
- Is Part Of:
- Journal of cellular and molecular medicine. Volume 26:Issue 20(2022)
- Journal:
- Journal of cellular and molecular medicine
- Issue:
- Volume 26:Issue 20(2022)
- Issue Display:
- Volume 26, Issue 20 (2022)
- Year:
- 2022
- Volume:
- 26
- Issue:
- 20
- Issue Sort Value:
- 2022-0026-0020-0000
- Page Start:
- 5246
- Page End:
- 5256
- Publication Date:
- 2022-09-07
- Subjects:
- amino acid transporter -- anti‐cancer agent -- global translation -- inhibitor -- large neutral amino acids -- LAT1 -- PDAC -- SLC7A5
Cytology
Medicine
Molecular Biology
Cytologie -- Périodiques
Médecine -- Périodiques
Biologie moléculaire -- Périodiques
Cytology -- Periodicals
Medicine -- Periodicals
Molecular biology -- Periodicals
611.01805 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934 ↗
http://www.blackwell-synergy.com/loi/jcmm ↗
http://www.usc.edu/hsc/nml/e-resources/info/joucelmm.html ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/jcmm.17553 ↗
- Languages:
- English
- ISSNs:
- 1582-1838
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4955.005000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24280.xml